This study was designed by big pharma to kill algenpantucel by creating the environment where salvage treatment was the true goal, all at the expense of NLNK investors. IMPRESS was doomed to fail since 2012, PILLAR is the only hope, where subgroups may show disease progression benefits.
No doubt, even some of the salvage treatments were approved after the start of IMPRESS, way to keep the control group inside the study margins. This study is more about salvage treatment efficy than it is about algenpantucel
I don't have a problem with him selling (it's just proof he's only in it for the money), the problem I have is for the 2nd interim they knew the outcome 3 months in advance of the PR. All during this time he sold a large amount of shares in the $50's. I can only assume the same is occurring now with the final outcome already being known, but I suspect Link is delaying by scheduling FDA and DSMC meetings to discuss the outcome (i.e. changing the analysis method). The SEC should be all over Newlink for withholding material information for as long as they do.
If the trial fails, the company will request meetings with the FDA and delay releasing the info for up to 6 months. All while the dirty Link sells 40k shares each month in between.
He traded twice after hearing the results of the 2nd interim, while making the market wait 2 months before releasing the data.
Link #$%$ waited 12 extra days to get his $400k bonus check. I can't wait until he is sued for trade while having material infomation. I guarantee he already has the results.
Plus, it is the first time in 2 years that Link didn't raid the corporate coffers with another 25,000 share sell.
222 event was Feb 2014, the DMSC schedule the review for the first week in March, reported the following week. 333 event was Feb 2015, link tried get the statistics modified for 2 months before giving up and finally telling the market of missed targets in May, 444 event in Feb 2016?